Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
03 June 2024 - 11:18PM
Business Wire
- Data from study using Guardant360® blood test show Black
patients with PIK3CA mutations in advanced breast cancer were less
likely than White patients to be enrolled in clinical trials and
receive targeted therapy
- Study is part of collaboration between Guardant Health and
Multicenter Precision Medicine Academic Consortium (PMAC) using
liquid biopsy to achieve equitable use of precision medicine
therapies in patients with metastatic breast cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, announced its research collaborators from Washington
University’s Siteman Cancer Center will lead an oral presentation
today at the 2024 American Society for Clinical Oncology (ASCO)
Annual Meeting highlighting the potential role of liquid biopsy in
addressing racial inequities in enrollment in clinical trials and
in the use of targeted therapies for advanced breast cancer.
The Rapid Oral Abstract Session (#1017), titled “Racial
differences in genomic profiles and targeted treatment use in ER+
HER2- metastatic breast cancer,” will be held between 11:30 am and
1:00 pm CT in Hall D1.
The retrospective study, led by first author Emily Podany, MD,
and senior author Andrew Davis, MD, both from Washington
University, focused on patients with hormone receptor positive
(HR+), HER2 negative (HER2-) metastatic breast cancer with PIK3CA
mutations, which had an equal incidence in Black and White
patients. The 1,327 patients in the study, who were treated at
Washington University in St. Louis, Massachusetts General Hospital,
and Northwestern University, had the Guardant360 liquid biopsy test
as part of clinical care and these results were combined with
annotated clinical data. Results indicated that Black patients were
significantly less likely than White patients to receive PIK3CA
targeted therapy or to be enrolled in a clinical trial for
biomarkers that required targetable mutations identified via
circulating tumor DNA (ctDNA). There were no differences in the use
of therapies that did not require a targetable mutation identified
via ctDNA.
“These data show clinical inequities in the use of targeted
therapies and enrollment in clinical trials, which must be the
focus of future interventions,” said Podany. “We must now identify
ways to ensure all patients equitably receive the recommended
precision medicine treatments based on the results of ctDNA
testing.”
“These data highlight the importance of using ctDNA to identify
targetable mutations,” noted Davis. “And they reinforce the urgent
need to ensure equitable implementation of precision medicine
therapies for patients of all races.”
The study is part of an ongoing collaboration between Guardant
Health and the multicenter Precision Medicine Academic Consortium
(PMAC) aimed at advancing the use of liquid biopsy in patients with
metastatic breast cancer.
“This landmark study highlights the importance of equitable
access to precision medicine,” said Craig Eagle, MD, chief medical
officer of Guardant Health. “The results confirm the potential role
liquid biopsy can have in helping researchers and clinicians
equitably match patients with appropriate trials and clinically
effective therapies.”
Currently, PMAC is working with Guardant Health to validate
genomic findings from this and prior projects using the
GuardantINFORM clinical-genomic dataset of over 400,000 patients
with advanced cancer. The collaboration will continue to pursue
future research focused on increasing equitable utilization of
targeted therapies.
“The current study demonstrates the importance of studying
real-world annotated molecular data related to the use of ctDNA
testing and targeted therapies in advanced cancer,” said Massimo
Cristofanilli, MD, co-founder of PMAC. “It provides valuable
insights that can help us understand the complex relation among
biological, ethnic and social diversity and offers potential tools
to overcome inequity in care.”
The full abstract for the study and a list of all abstracts
being presented at the meeting can be found at the ASCO
website.
For more information and updates from the meeting, follow
Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth
#28115.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2023, and in
its other reports filed with or furnished to the Securities and
Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant
Health as of the date hereof, and Guardant Health disclaims any
obligation to update any forward-looking statements provided to
reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is based,
except as required by law. These forward-looking statements should
not be relied upon as representing Guardant Health’s views as of
any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240602799783/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
317-371-0035
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2024 to Jun 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Jun 2023 to Jun 2024